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Background
Ritonavir-boosted darunavir (DRV/r) and etravirine (ETR)
in DUET trials and raltegravir (RAL) in BENCHMRK trials
have shown high rates of virological responses in treat-
ment-experienced patients with multi-drug resistant HIV-
infection, particularly when used in association with two
more fully active antiretroviral drugs. However, the com-
bination of DRV/r, ETR and RAL has not been evaluated.
Methods
Prospective observational study of all consecutive HIV-1
infected adults with virological failure and very limited
treatment options, who started a new salvage regimen
with DRV/r (600/100 mg twice daily), ETR (200 mg twice
daily) and RAL (400 mg twice daily), from April 2007
through January 2008 in two hospitals in Spain. Clinical
evaluation and immunological, virological and biochem-
ical tests were performed at baseline and at week 4, 12 and
24.
Summary of Results
Overall there were 32 patients: 23 were male and all Cau-
casian. Median baseline characteristics were: age 44 years,
16 years since HIV diagnosis, 13 years on antiretroviral
therapy (ART), nine prior HAART regimens, CD4 count
261 cells/mL and HIV-1 RNA 4.2 log10 copies/mL. Six-
teen (50%) and 14 (44%) were enfuvirtide and tipranavir
experienced, respectively. At baseline, all patients har-
boured three-class resistance mutations, with a median of
five IAS-USA primary PI resistance mutations (75% had
four or more), two NNRTI mutations and five NRTI muta-
tions (four TAMs) at baseline. Three patients (9%) har-
boured three ETR resistance mutations. All patients were
DRV-naïve and had a median of one (0–3) DRV resistance
mutation. The percentage of patients (ITTnc = f) with
HIV1-RNA below 50 copies/mL was 63% (20/32) at week
4, 81% (26/32) at week 12 and 94% (30/32) at week 24.
Only two patients did not achieved virological suppres-
sion: one stopped treatment at week 4 and the other had
poor adherence overtime. Median CD4 cell count
increased 30, 73 and 103 cells/mL at week 4, 12 and 24,
respectively. None of the patients had adverse events lead-
ing to discontinuation of the regimen.
Conclusion
The combination of DRV/r, ETR and RAL was a highly
effective and well tolerated antiretroviral salvage regimen
in patients with multi-drug resistant HIV1-infection.
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